Company Filing History:
1 out of 23 
1 out of 1 
1 out of 23 
Years Active: 2008-2021
Title: The Innovative Contributions of Peter Muhlradt
Introduction
Peter Muhlradt is a notable inventor based in Braunschweig, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic and prophylactic vaccinations. With a total of 3 patents, his work has had a considerable impact on immunology and vaccine development.
Latest Patents
One of his latest patents is focused on the use of lipopeptides or lipoproteins as adjuvants in therapeutic or prophylactic vaccinations. This invention discloses the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. The lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2R)-propyl at the amino-terminal cysteine of a peptide or protein. These peptides are highly effective even in small doses, producing good immunization results and increasing the IgA level, among other benefits.
Another significant patent relates to a therapeutical composition containing dendritic cells and its use. This invention describes a method for preparing a therapeutical composition, particularly involving the treatment of dendritic cells with a combination of at least one interferon gamma receptor agonist and at least one toll-like receptor 2 and/or TLR 6 agonist. The pretreated dendritic cells are then used for the preparation of a therapeutical composition aimed at treating various diseases and disorders.
Career Highlights
Throughout his career, Peter Muhlradt has worked with prominent organizations such as Helmholtz-Zentrum für Infektionsforschung GmbH and GBF Gesellschaft für Biotechnologische Forschung mbH. His work in these institutions has allowed him to advance his research and contribute to significant innovations in the field.
Collaborations
Peter has collaborated with notable colleagues, including Armin Braun and Norbert Krug. These partnerships have further enriched his research and development efforts.
Conclusion
Peter Muhlradt's innovative work in biotechnology and vaccine development has led to important advancements in immunology. His patents reflect a commitment to improving therapeutic methods and enhancing vaccination efficacy. His contributions continue to influence the field and pave the way for future innovations.